Editas Medicine $125 million follow-on offering
The stock is listed on the Nasdaq Global Select Market
Davis Polk advised the joint book-running managers in connection with the $125 million offering of 12,500,000 shares of common stock of Editas Medicine, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “EDIT.”
Editas Medicine is a clinical-stage genome editing company, focused on translating the power and potential of the CRISPR/Cas12a and Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Marcel Fausten and associate Michael Stromquist. Partner David R. Bauer and associates Alison T. Chin and Anthony Tran provided intellectual property advice. The tax team included Kara L. Mungovan and associate Ted Lee. All members of the Davis Polk team are based in the New York office.